Nix 0699

Drug Profile

Nix 0699

Alternative Names: Hemoxin; Nicosan; Niprisan

Latest Information Update: 13 Jul 2006

Price : $50

At a glance

  • Originator National Institute for Pharmaceutical Research and Development
  • Class Antianaemics; Phytotherapies
  • Mechanism of Action Haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Sickle cell anaemia

Most Recent Events

  • 06 Jul 2006 Launched for Sickle cell anaemia in Nigeria (PO)
  • 06 Jul 2006 First global launch of Nix 0699 [Nigeria]
  • 03 Jul 2006 Registered for Sickle cell anaemia in Nigeria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top